Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock

Argenx SE (NASDAQ:ARGX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now.

On March 2, James Gordon of Barclays maintained his Buy rating on argenx SE (NASDAQ:ARGX), along with a €900 price target. On February 27, Robert W. Baird increased its price target on argenx SE while reaffirming a Neutral rating. Analyst Colleen M. Kusy raised the firm’s price target on the stock from $858 to $867. The firm revised its financial model after reviewing the company’s fourth-quarter earnings report. The Q4 results reflected continued strength in revenue performance as well as an updated outlook pointing to higher operating expenses.

In contrast to Baird, Stifel Nicolaus reduced its price target on Argenx following the company’s Q4 fiscal 2025 results. On February 26, Stifel Nicolaus analyst Alex Thompson lowered the firm’s price target on the stock from $1,248 to $1,227 while maintaining a Buy rating.

The analyst highlighted that the Vyvgart launch continues to perform well, with the franchise now generating more than $5 billion in annual global revenue. The firm said that the management’s steady outlook for 2026 and the years ahead suggests the current consensus forecast of  $5.7 billion could be too low, even with growing competition and typical first-quarter seasonality.

Photo by RephiLe water on Unsplash

argenx SE (NASDAQ:ARGX) operates as a commercial-stage biopharma company. The company focuses on developing several therapies for the treatment of autoimmune diseases in the Netherlands, Japan, the United States, China, and globally. It offers VYGART HYTRULO and VYGART.

While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

.

Disclosure: None.